雖然這篇EMPEROR-Preserved鄉民發文沒有被收入到精華區:在EMPEROR-Preserved這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]EMPEROR-Preserved是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Empagliflozin in Heart Failure with a Preserved Ejection Fraction
The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) was carried out to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Empagliflozin in Heart Failure with a Preserved ... - PubMed
EMPEROR -Preserved Trial Investigators: D Aizenberg, L Cartasegna, H Colombo, J Fernandez Mouti, M Koretzky, J Archibaldo Glenny, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3EMPagliflozin outcomE tRial in Patients With ... - Clinical Trials
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) ... Brief Summary: This is a study in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Empagliflozin Outcome Trial in Patients With Chronic Heart ...
The EMPEROR-Preserved trial showed that empagliflozin is superior to placebo in improving HF outcomes among patients with symptomatic stable ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5EMPEROR-Preserved: Empagliflozin Improves Outcomes in ...
EMPEROR -Preserved: Empagliflozin Improves Outcomes in HFpEF · (UPDATED) It's “a big day for patients living with HFpEF, a big day for heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6emperor-preserved-heart-failure-full-data | Boehringer Ingelheim
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7Empagliflozin, Health Status, and Quality of Life in Patients ...
Background: Patients with heart failure and preserved ejection fraction (HFpEF) have ... In EMPEROR-Preserved, we evaluated the efficac...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Preview EMPEROR-Preserved: A promise fulfilled - Science ...
In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Empagliflozin in heart failure with preserved or mildly ... - NERDCAT
EMPEROR -Preserved secondary paper on quality of life. Circulation 2021. Bottom Line: In patients with symptomatic heart failure with preserved ( ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10EMPEROR-Preserved Trial of SGLT2 inhibitors in HFpEF
The EMPEROR-Program is really a programme of studies in heart failure with reduced ejection fraction, and yes, mid-range ejection fraction, and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11EMPEROR-Preserved First Trial to Show Positive Results in ...
For the first time, a clinical trial has successfully shown that a therapy can cut the risk of hospitalization and cardiovascular death for ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12Emperor-Preserved trial: what will change for patients with ...
With the presentation of the Emperor-Preserved trial at the 2021 European Society of Cardiology (ESC) Congress and its subsequent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13EMPEROR-Preserved: A Win for Empagliflozin - NEJM ...
EMPEROR -Preserved: A Win for Empagliflozin ... The SGLT-2 inhibitor improved outcomes for patients with heart failure and preserved ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14EMPEROR-Preserved - Wiki Journal Club
Published in 2021, EMPEROR-Preserved trial randomized about 6,000 patients with NYHA class II-IV symptoms, LVEF >40% (i.e., HFmrEF and HFpEF), ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15Design for the EMPEROR-Preserved Trial. - ResearchGate
... The EMPEROR-preserved trial [65] is a multicenter, randomized, double-blind, parallel-group, placebo-controlled trial that was ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16EMPEROR-Preserved Trial
EMPEROR -Preserved Trial. Empagliflozin Outcome Trial in Patients with Chronic. Heart Failure with Preserved Ejection Fraction.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Advanced CKD Doesn't Derail Empagliflozin in EMPEROR ...
EMPEROR -Preserved is the first prospective, randomized trial to unequivocally show the efficacy and safety of a drug for improving outcomes in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18European Society of Cardiology 在Twitter 上:"#EMPEROR ...
#EMPEROR-Preserved trial: empagliflozin reduces the risk of a composite of #cardiovascular death or hospitalisation for #heartfailure in patients with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Breakthrough results for Jardiance® (empagliflozin ... - Investors
EMPEROR -Preserved, in adults with chronic heart failure with preserved ejection fraction to reduce the risk of cardiovascular death or hospitalization due to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20EMPEROR-Preserved: Empagliflozin reduces risk for serious ...
In patients with HF with preserved ejection fraction, empagliflozin reduced risk for serious hospitalizations compared with placebo, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Emperor - Preserved | NB Medical
Emperor - Preserved. I am, by nature, a late adopter in life. Whether it's fads, tech or fashion I tend to let things roll for a bit to see ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22HFpEF & diabetes
Keep up with the latest news and expert views on heart failure with preserved ejection fraction following the publication of EMPEROR-Preserved data.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23EMPEROR-Preserved findings confirmed in 'true' HFpEF ...
About one-third of the 5,988 patients enrolled in EMPEROR-Preserved had an LVEF of 41%-49%, heart failure with mildly reduced ejection fraction.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24CardsJC: EMPEROR-Preserved Trial - CardioNerds
EMPEROR -Preserved Trial: Empagliflozin in Heart Failure with a Preserved Ejection Fraction is discussed as part of the CardioNerds #CardsJC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25Breakthrough results for Jardiance® (empagliflozin) confirm ...
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#262021 Top Story in Cardiology: EMPEROR-Preserved
Heart failure with preserved ejection fraction (HFpEF) represents a ... The EMPEROR-Preserved trial showed benefits up to an ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27rationale for and design of the EMPEROR‐Preserved Trial
Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#281245.110 EMPEROR-Preserved Study - Health Research ...
This is a phase III study in patients with symptomatic chronic heart failure (HF) with preserved ejection fraction (Left Ventricular Ejection Fraction >40%) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29EMPEROR-Preserved Data Summary Slide
EMPEROR -Preserved: Empagliflozin Outcome Trial in Patients with Chronic Heart failure with. Preserved Ejection Fraction. Purpose:.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Q&A on EMPEROR-Preserved With Javed Butler, MD
In an interview with Practical Cardiology, Javed Butler, MD, offers his perspective on the results of EMPEROR-Preserved and reflects on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31中央社訊息平台
中央社訊息服務20210707 09:46:14)- The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32Empagliflozin benefits heart failure patients with reduced and ...
Results of the EMPEROR-Preserved trial, presented at ESC Congress 2021, demonstrated that the drug also reduced this composite cardiovascular ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33The SGLT2 inhibitor dapagliflozin in heart failure with ... - Nature
Patients with heart failure and preserved ejection fraction (HFpEF) ... KCCQ-CS seen with empagliflozin versus placebo in EMPEROR-PRESERVED, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34The first successful trial to improve outcomes in HFpEF - MIMS ...
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Eli Lilly and Boehringer Ingelheim's Jardiance Shows Benefits ...
August 27, 2021— Eli Lilly and Company and Boehringer Ingelheim announced that the full results from the landmark EMPEROR-Preserved phase 3 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Duygu İnan). Reviwer: Dr. Duygu İnan. Name of the study : Empagliflozin in Heart Failure with a Preserved Ejection Fraction- EMPEROR- Preserved. Presented ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37EMPEROR-Preserved : L'Empagliflozine est efficace dans l ...
D'après la présentation de Stefan Anker (Berlin, Allemagne) : "Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% - Results ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38Eli Lilly Says EMPEROR-Preserved Phase III Trial Of ...
(RTTNews) - Boehringer Ingelheim and Eli Lilly and Co. (LLY) announced Tuesday that the EMPEROR-Preserved phase III trial met its primary ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39More Good News for Empagliflozin in Patients With Heart Failure
Slower renal function decline with SGLT-2 inhibitor in EMPEROR-Preserved trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Empagliflozin Reduces Risk of CV Death, Hospitalization for ...
The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41FDA Grants Empagliflozin Breakthrough Therapy Status for ...
Designation based on results from the EMPEROR-Preserved phase III trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42ESC 2021 – Jardiance blows Entresto out of the water | Evaluate
Emperor -Preserved enrolled patients with an LVEF of 40% or greater, meaning that it captured some patients with HFmrEF. So one concern could be ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43Jardiance demonstrates benefits for patients with heart failure ...
The Emperor-Preserved trial demonstrated that Jardiance significantly reduces the risk of the composite primary endpoint of cardiovascular death ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Presenter Perspectives: Landmark Trials in Heart Failure ...
... Trials in Heart Failure—DELIVER and EMPEROR-Preserved—Will SGLT2 Inhibitors Succeed in Heart Failure with Preserved Ejection Fraction?
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Landmark trial demonstrates empagliflozin is the first therapy ...
EMPEROR -Preserved included 5,988 people with heart failure. 1 Of these, 4,005 had a left ventricular ejection fraction (LVEF) of 50 percent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Preserved (empagliflozin in preserved ejection fraction heart ...
Anker et al undertook the EMPEROR-Preserved trial which aimed to evaluate the efficacy and safety of the SGLT2 inhibitor empagliflozin ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47HF hospitalizations reduced by SGLT2 inhibitor across broad ...
EMPEROR -Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48EMPEROR-Preserved: Empagliflozin first therapeutic agent to ...
The EMPEROR-Preserved trial explored the effect of the SGLT2 inhibitor empagliflozin in people living with heart failure with preserved ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49EMPEROR-Preserved: landmark trial in heart failure research
EMPEROR -Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Breakthrough results for Jardiance® (empagliflozin) confirm ...
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51EMPEROR Preserve and what it means - Cardiovascular ...
What William Harvey, in 1785, called dropsy [1] turned out to be heart failure with reduced ejection fraction (HFrEF), water retention and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52EMPEROR-Preserved: 'A win against a formidable foe'
The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) is a trial of the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53A Meta-Analysis of the Sodium-Glucose Cotransporter 2 ...
Recently, the results of the EMPEROR-Preserved trial (Empagliflozin in Heart Failure with a Preserved Ejection Fraction) were released and it ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Breakthrough results for empagliflozin confirm EMPEROR ...
The EMPEROR-Preserved Phase III trial met its primary endpoint, establishing empagliflozin as the first and only therapy to significantly ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Empagliflozin EMPEROR-Preserved trial announces ...
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as the first successful trial for heart failure with preserved ejection ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56EMPEROR-Preserved: main results - Virtual Meeting | EASD
Session: EMPEROR Preserved Study. VM 2021. Athens Hall. 30. September 2021 16:23 - 16:33. 563 views. The publication of this presentation was not agreed.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Breakthrough Results for Jardiance ... - Pharma's Almanac
Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58新英格兰医学杂志 - X-MOL
The EMPEROR- Preserved study: end of the search for the “Phoenix” or beginning of a new season for trials in heart failure with preserved ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59Breakthrough results for Jardiance® (empagliflozin) confirm ...
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60Boehringer and Lilly report positive data from EMPEROR ...
The trial evaluated the safety and efficacy of Jardiance (empagliflozin) in patients with chronic heart failure with preserved ejection fraction ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61EMPEROR-Preserved_循環器トライアルデータベース - EBM ...
今回,EMPEROR-Preserved 試験でempaglifrozinが初めてその有効性を示したことは画期的である。本試験は,心血管死と心不全による入院の複合エンドポイントで評価して ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62EMPEROR-Preserved - Slideshare
Diego Segura Rodríguez EMPEROR-Preserved Anke, SD et al. NEJM 2021; 3. Diego Segura Rodríguez EMPEROR-Preserved La IC con FEVI preservada afecta a millones ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63ASN Kidney Week 2021 - Late-Breaking Clinical Trials
12:00 p.m. FR-OR67 EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection. Fraction and CKD - Faiez Zannad ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64#ESCCongress: Results of the EMPEROR-Preserved Trial ...
However, a major difference between EMPEROR-Reduced and EMPEROR-Preserved was that in the REDUCED trial, enrolled patients had heart failure and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65New empagliflozin data shows statistically significant ...
EMPEROR -Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66EMPEROR-Preserved - Universitätsklinikum des Saarlandes
EMPEROR -Preserved ... Chronic HF with preserved EF defined as LVEF > 40 % per local reading (obtained by echocardiography, radionuclide ventriculography, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67ESC 2021: novo paradigma no tratamento da ICFEP
Foi apresentado no congresso da European Society of Cardiology (ESC 2021) os resultados do estudo EMPEROR-Preserved. Saiba mais.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68The Emperor-Preserved trial: what will change for patients ...
The Emperor-Preserved trial: what will change for patients with heart failure with preserved ejection fraction?. European Journal of Cardiovascular Nursing ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69EMPagliflozin outcomE tRial in patients ... - Cochrane Library
EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure EMPEROR-Preserved. EUCTR2016‐002278‐11‐BE. https://trialsearch.who.int/Trial2.aspx?
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Empagliflozin Linked to Risk Reduction of Heart Failure with ...
The EMPEROR-Preserved Phase 3 trial met its primary endpoint, demonstrating empagliflozin (Jardiance) significantly reduced the risk of a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Heart failure with preserved ejection fraction | BCS - British ...
Ongoing studies (DELIVER and EMPEROR-Preserved) will evaluate the effects of SGLT-2 inhibitors, a class of agent with striking efficacy in heart failure ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Breakthrough results for Jardiance ... - PR Newswire
EMPEROR -Preserved, in adults with chronic heart failure with preserved ejection fraction to reduce the risk of cardiovascular death or ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Empagliflozin reduces hospitalisation risk for heart patients
The breakthrough results of Boehringer Ingelheim's EMPEROR-Preserved trial reveal that Empagliflozin reduces the combined relative risk of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74EMPEROR-Preserved spouts torrent of reports on ...
The featured report from the 6000-patient EMPEROR-Preserved trial at the virtual annual congress of the European Society of Cardiology drew ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Trial reports first successful results for heart failure with ...
EMPEROR -Preserved trial presented in a Hot Line Session today at ESC ... and a preserved ejection fraction (HFpEF) with or without diabetes.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76New heart failure data for SGLT2 inhibitors - McGill University
Results of the EMPEROR Reduced Trial. Javed Butler, MD MPH MBA ... *The cut off for patients with AF is doubled in EMPEROR-Reduced. ... EMPEROR-Preserved.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77EMPEROR-Preserved: punto de partida con empagliflozina ...
EMPEROR -Preserved: punto de partida con empagliflozina en insuficiencia cardiaca preservada ... Este fin de semana se celebra la AHA Scientific ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78EMPEROR-Preserved e EMPEROR-Pooled. Quali i risultati ...
Marco Metra, Editor-in-chief dell'European Journal of Heart Failure, commenta sugli studi EMPEROR-Preserved e EMPEROR-Pooled.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Evaluation of the effects of sodium-glucose co-transporter 2 ...
... and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80Empagliflozin has broad beneficial effect on HFpEF outcomes
Further EMPEROR-Preserved analysis shows significant risk reductions for a broad range of inpatient and outpatient HF outcomes with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Association of SGLT2 Inhibitors With Cardiovascular and ...
... with reduced and preserved ejection fraction and chronic kidney ... heart failure with preserved ejection fraction (EMPEROR-Preserved).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82BI/Lilly's Jardiance Crowned As Heart Failure Game Changer ...
BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved. 'Unequivocal Benefit' Unveiled At ESC. 29 Aug 2021 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Webinar on 'Emperor Preserved' Trial | Lupin India | Facebook
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Boehringer Ingelheim 糖尿病口服藥治療心臟衰竭3 期臨床數據
EMPEROR -Preserved 共招募5,988 位受試者,試驗組每日使用10mg 的Jardiance,安慰劑組則使用安慰劑。該試驗主要觀察Jardiance 對HFpEF 患者的有效性與 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Are SGLT-2 Inhibitors the Future of Heart Failure Treatment ...
The EMPEROR-preserved trial is the first randomised placebo‐controlled trial to explore the impact of SGLT-2 inhibitors in the treatment of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Breakthrough Results Confirm Empagliflozin as First, Only ...
“The totality of the data from the EMPEROR-Preserved trial marks a possible new chapter in heart failure, supporting the potential of Jardiance ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87EMPEROR-Preserved confirms success of Empagliflozin in ...
The EMPEROR-Preserved trial demonstrated that empagliflozin is safe ... HF with preserved ejection fraction, regardless of diabetes status.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88[EMPEROR-Preserved] Expert Opinion and Summary
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Kangxi Emperor - Wikipedia
The Chahar Mongols were then put under the direct control of the Qing Emperor unlike the other Inner Mongol leagues which maintained their autonomy.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90The Secret Tomb of China's 1st Emperor: Will We Ever See ...
An army of clay warriors guards the tomb of China's first emperor, ... where they can actually preserve the paint as they excavate.".
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91絹川 弘一郎 氏)-1473|医師向け医療ニュースはケアネット
サクビトリル・バルサルタンはとても良い心不全治療薬である。もう少し正確に言うと素晴らしい軽症心不全治療薬である。Paradigm-HFやLifeのデータを見てもNYHA 4度に ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92CardioScripts Podcast on Apple Podcasts
The EMPEROR-Preserved Trial. Dr. Alex Goncharenko and CardioScripts co-host, Dr. Elisabeth Wang, discuss the EMPEROR-Preserved Trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93Cardiovascular Medicine Research, News & Clinical Resources
Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved Trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94'자디앙® 심장동(動)감 심포지엄' 성료 - 이엠디
EMPEROR -Preserved‡ [NCT03057951]는 심박출률이 보존된 만성 심부전 환자(HFpEF)에서 자디앙의 안전성과 유효성을 평가한다.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
emperor-preserved 在 コバにゃんチャンネル Youtube 的精選貼文
emperor-preserved 在 大象中醫 Youtube 的最讚貼文
emperor-preserved 在 大象中醫 Youtube 的最佳貼文